Low skeletal muscle mass and liver fibrosis in children with cerebral palsy.
Altered body composition
Cerebral palsy
Liver fibrosis
Low skeletal muscle mass
Steatosis
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
05
05
2023
accepted:
23
08
2023
revised:
21
08
2023
medline:
13
11
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
ppublish
Résumé
The purpose of the study was to conduct a nutritional and metabolic assessment of children with cerebral palsy, including an investigation of liver status, body composition, and bone mineral density. In this cross-sectional study we included 22 children with cerebral palsy. By using ultrasound, transient elastography, dual x-ray absorptiometry (DXA) scan, blood samples, anthropometric measurements, and a three-day diet registration, the nutritional and metabolic status was evaluated. Liver fibrosis and steatosis were found in four patients (18.2%), all with severe motor impairments, low skeletal muscle mass, and epilepsy. All patients with liver involvement had normal liver-related blood samples. Decreased bone mineral density was found in 26.3%, and 91.0% had low skeletal muscle mass. Fat mass and muscle mass were significantly lower in the patients with severe motor impairments compared to the patients with less severe motor impairments. Within the children classified as 'underweight' or 'normal' according to body mass index, body fat determined by DXA scan was normal or high in 50% of these patients. This study is the first to report liver fibrosis and steatosis in children with cerebral palsy. Possible causes of liver fibrosis and/or steatosis are altered body composition with low skeletal muscle mass, decreased mobility and medical drug intake. Further investigations of liver involvement and risk factors are needed. • Children and adolescents with cerebral palsy are at risk of malnutrition and altered body composition, both of which can lead to fatty liver disease. • It is unknown whether children with cerebral palsy are at increased risk of metabolic disturbances such as fatty liver disease. • Altered body composition and low skeletal muscle mass, regardless of ambulation is present in 91% of the children with cerebral palsy. • Liver fibrosis and/or steatosis were found in 18.2% of the patients. Possible causes are altered body composition, decreased mobility and medical drug intake.
Identifiants
pubmed: 37656239
doi: 10.1007/s00431-023-05177-9
pii: 10.1007/s00431-023-05177-9
pmc: PMC10640414
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5047-5055Subventions
Organisme : Elsass Fonden
ID : 18-3-0451
Informations de copyright
© 2023. The Author(s).
Références
Pediatr Int. 2022 Jan;64(1):e15005
pubmed: 34585809
Phys Med Rehabil Clin N Am. 2020 Feb;31(1):25-37
pubmed: 31760992
J Pediatr Gastroenterol Nutr. 2013 Jan;56(1):72-6
pubmed: 22922372
Clin Liver Dis. 2004 Aug;8(3):549-58, viii-ix
pubmed: 15331063
Pediatrics. 2002 Jul;110(1 Pt 1):e5
pubmed: 12093986
Int J Obes (Lond). 2005 Jan;29(1):1-8
pubmed: 15278104
Nutrients. 2022 Feb 09;14(4):
pubmed: 35215377
J Pediatr Gastroenterol Nutr. 2013 Jul;57(1):109-13
pubmed: 23539048
Dev Med Child Neurol. 2006 Nov;48(11):877-82
pubmed: 17044953
Eur J Pediatr. 2019 Jun;178(6):811-822
pubmed: 30877384
Dev Med Child Neurol. 2019 Apr;61(4):477-483
pubmed: 30663044
J Pediatr. 2017 Aug;187:141-146.e1
pubmed: 28366357
Dev Med Child Neurol. 2015 Sep;57(9):858-64
pubmed: 25827868
Eur J Clin Nutr. 2013 Dec;67 Suppl 2:S13-6
pubmed: 24301003
Saudi J Biol Sci. 2022 Apr;29(4):2007-2013
pubmed: 35531196
Osteoporos Int. 2015 Jan;26(1):141-50
pubmed: 25119201
Pediatrics. 2011 Aug;128(2):e299-307
pubmed: 21768315
Arch Pediatr. 2020 Feb;27(2):95-103
pubmed: 31791829
Disabil Rehabil. 2006 Feb 28;28(4):183-91
pubmed: 16467053
Int J Endocrinol. 2015;2015:867273
pubmed: 26089900
Neuromuscul Disord. 2009 Jun;19(6):391-6
pubmed: 19427208
Dev Med Child Neurol. 2000 Mar;42(3):162-8
pubmed: 10755455
Metabolism. 2019 Oct;99:102-112
pubmed: 31348927
Arch Phys Med Rehabil. 2017 Nov;98(11):2295-2300
pubmed: 28465219
Ann Nutr Metab. 2015;66(4):224-232
pubmed: 26111638
J Trace Elem Med Biol. 2021 Mar;64:126685
pubmed: 33249374
J Clin Endocrinol Metab. 2006 Dec;91(12):4753-61
pubmed: 16968800
Dev Med Child Neurol. 2010 Feb;52(2):e35-41
pubmed: 19811518
J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):242-264
pubmed: 28737572
Acta Paediatr. 2023 Apr;112(4):846-853
pubmed: 36579362
J Hepatol. 2016 Dec;65(6):1198-1208
pubmed: 27312946
J Pediatr. 2009 May;154(5):715-20
pubmed: 19111321
J Nutr. 2007 Jan;137(1):153-7
pubmed: 17182818
Ann Gastroenterol. 2021;34(3):404-414
pubmed: 33948067
Public Health. 2022 Apr;205:192-201
pubmed: 35339939
Dev Med Child Neurol. 1997 Apr;39(4):214-23
pubmed: 9183258
Dev Med Child Neurol. 2017 Sep;59(9):933-938
pubmed: 28656704
Acta Paediatr. 2021 Dec;110(12):3367-3375
pubmed: 34407566
Pediatr Res. 1991 Jan;29(1):70-7
pubmed: 2000262
Dev Med Child Neurol. 2010 Sep;52(9):824-30
pubmed: 20497455
Clin Nutr. 2019 Oct;38(5):2002-2015
pubmed: 31031136
Neurologia (Engl Ed). 2021 Mar;36(2):112-118
pubmed: 29342407